IMGN ImmunoGen Inc.

-0.07  -3%
Previous Close 2.53
Open 2.53
Price To Book 35.14
Market Cap 367548170
Shares 149,409,825
Volume 3,143,382
Short Ratio
Av. Daily Volume 3,717,748

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 triplet and mature doublet expansion cohort data due 2019.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data did not meet primary endpoint - March 1, 2019.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 updated data due 2019.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Phase 1 additional data due at ASH December 1, 2018 noted 26% ORR; 7% CR.
Relapsed/refractory acute myeloid leukemia (AML)

Latest News

  1. ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
  2. ImmunoGen Stock Is in Trouble Going Into Earnings
  3. Here's Why ImmunoGen Tumbled 43% in March
  4. Do Directors Own ImmunoGen, Inc. (NASDAQ:IMGN) Shares?
  5. Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock
  6. ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?
  7. ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates
  8. Four Biotech Stocks Setting The Standard on Wednesday
  9. Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
  10. Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks
  11. Why ImmunoGen Tanked on Friday
  12. Immunogen Inc (IMGN) Files 10-K for the Fiscal Year Ended on December 31, 2018
  13. Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint
  14. Why ImmunoGen Stock Is Crashing Today
  15. Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail
  16. Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint
  17. ImmunoGen's ovarian cancer drug fails in late-stage study
  18. ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
  19. Why ImmunoGen Tumbled 20.3% Today
  20. ImmunoGen Announces Multiple Presentations at AACR Annual Meeting